Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial.

Clowse MEB, Isenberg DA, Merrill JT, Dörner T, Petri M, Vital EM, Morand EF, Touma Z, Askanase AD, Ioannou Y, Brookes S, Gaiha-Rohrbach J, Koch ED, Zibian N, Martin C, Jimenez T, Nelde A, Stach C, PHOENYCS GO Study Investigators’ Group

Open source

DOI: 10.1016/s0140-6736(26)00691-4
Published: 2026 Jun 6
Container: Lancet (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-00691-4,
  title = {Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial.},
  author = {Clowse MEB and Isenberg DA and Merrill JT and Dörner T and Petri M and Vital EM and Morand EF and Touma Z and Askanase AD and Ioannou Y and Brookes S and Gaiha-Rohrbach J and Koch ED and Zibian N and Martin C and Jimenez T and Nelde A and Stach C and PHOENYCS GO Study Investigators’ Group},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(26)00691-4},
  url = {https://doi.org/10.1016/s0140-6736(26)00691-4}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial.
AU  - Clowse MEB
AU  - Isenberg DA
AU  - Merrill JT
AU  - Dörner T
AU  - Petri M
AU  - Vital EM
AU  - Morand EF
AU  - Touma Z
AU  - Askanase AD
AU  - Ioannou Y
AU  - Brookes S
AU  - Gaiha-Rohrbach J
AU  - Koch ED
AU  - Zibian N
AU  - Martin C
AU  - Jimenez T
AU  - Nelde A
AU  - Stach C
AU  - PHOENYCS GO Study Investigators’ Group
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(26)00691-4
UR  - https://doi.org/10.1016/s0140-6736(26)00691-4
ER  -

APA

MEB, C., DA, I., JT, M., T, D., M, P., EM, V., EF, M., Z, T., AD, A., Y, I., S, B., J, G., ED, K., N, Z., C, M., T, J., A, N., C, S., & Group, P. G. S. I. (2026). Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)00691-4

Source records

pubmed · retrieved 2026-09-26T06:01:03.288Z